F. B. Oldham
Impact in
- Hematology top 5%
- Hematopoietic Stem Cell Transplantation
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
Papers in
- Oncology 24
- Cancer Treatment and Pharmacology 13
- Colorectal Cancer Treatments and Studies 6
- Lung Cancer Research Studies 5
- Neutropenia and Cancer Infections 4
-
- Lung Cancer Treatments and Mutations 13
- Co-authors
- Jack W. Singer (11 shared papers)Stewart D. Chipman (1 shared paper)Gabriella Pezzoni (1 shared paper)Amy J. Eisenfeld (6 shared papers)B. Bandstra (4 shared papers)Mary O’Brien (5 shared papers)JG Bender (2 shared papers)D. Van Epps (2 shared papers)
- Journals
- Journal of Clinical Oncology (11 papers)Journal of Thoracic Oncology (5 papers)Blood (2 papers)Human Gene Therapy (1 paper)Clinical Lung Cancer (1 paper)
- Partner nations
- United StatesUnited KingdomIreland
In The Last Decade
F. B. Oldham
31 papers receiving 905 citations
Peers
Comparison fields: 5 of 78
- Hematology 300
- Biomaterials 253
- Oncology 397
- Genetics 112
- Immunology 106
Countries citing papers authored by F. B. Oldham
This map shows the geographic impact of F. B. Oldham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. B. Oldham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. B. Oldham more than expected).
Fields of papers citing papers by F. B. Oldham
This network shows the impact of papers produced by F. B. Oldham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. B. Oldham. The network helps show where F. B. Oldham may publish in the future.
Co-authors
The 25 scholars most cited alongside F. B. Oldham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1996 | 152 | |
| 2 | 2008 | 125 | |
| 3 | 1996 | 116 | |
| 4 | 2008 | 96 | |
| 5 | 2006 | 96 | |
| 6 | 1992 | 45 | |
| 7 | 1999 | 39 | |
| 8 | 1996 | 36 | |
| 9 | 2005 | 32 | |
| 10 | 2008 | 29 | |
| 11 | 2005 | 23 | |
| 12 | 2006 | 23 | |
| 13 | Phase I-II trial of high-dose epirubicin in patients with lymphoma. | 1987 | 20 |
| 14 | 1998 | 15 | |
| 15 | 2007 | 15 | |
| 16 | Phase I-II study of epirubicin in multiple myeloma. | 1988 | 14 |
| 17 | 2005 | 11 | |
| 18 | 1996 | 10 | |
| 19 | Mobilization and purification of CD34+ cells from normal donors-regimens with G-CSF, GM-CSF, or a combination of both. | 1996 | 7 |
| 20 | 2005 | 7 |
About F. B. Oldham
F. B. Oldham is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Hematology, Hepatology and Radiology, Nuclear Medicine and Imaging, having authored 31 papers that have together received 939 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (13 papers), Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (6 papers), Hematopoietic Stem Cell Transplantation (6 papers), Lung Cancer Research Studies (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Neutropenia and Cancer Infections (4 papers) and Immunotherapy and Immune Responses (3 papers). The work is most often cited by research in Hematology (300 citations), Biomaterials (253 citations), Oncology (397 citations), Genetics (112 citations) and Immunology (106 citations). F. B. Oldham has collaborated with scholars based in United States, United Kingdom and Ireland. Frequent co-authors include Jack W. Singer, Stewart D. Chipman, Gabriella Pezzoni, Amy J. Eisenfeld, B. Bandstra, Mary O’Brien, JG Bender, D. Van Epps, M Schilling and SF Williams. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Blood, Human Gene Therapy and Clinical Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.